Article Text
Abstract
A 48-year-old deaf-mute man attending our outpatient clinic for long-term severely decompensated type 1 diabetes (mean glycated haemoglobin over 100 mmol/mol) has proved to be the best candidate for the beneficial implant of a next-generation closed loop insulin pump featuring a new refined auto-correction algorithm. The patient had already worn a stand-alone real-time continuous glucose monitoring (rt-CGM) device for 2 years, but his haemoglobin A1c (HbA1c) remained out of target with ample glucose variability. Then, we decided to use a novel advanced hybrid closed-loop insulin pump (the MiniMed 780G) coupled with his CGM device. After only 4 months this system led to a significant improvement in mean daily glucose levels (201±100 mg/dL vs 141±57 mg/dL), time in glucose range (43% vs 78%), percentage of time spent in hyperglycaemia (52% vs 20%), glucose variability (Coefficient of Variation 46% vs 38%), and HbA1c levels (121 mmol/mol vs 56 mmol/mol). The patient was highly satisfied.
- diabetes
- ear
- nose and throat/otolaryngology
Statistics from Altmetric.com
Footnotes
Contributors BP and AN wrote the manuscript. IG and FB reviewed the manuscript. All authors approved the final manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.